论文部分内容阅读
McCauley等(1989年)和Brown与Ne—ild(1990年)均提出FK506的免疫抑制剂量不会造成如环孢菌素中所见到的血管内皮影响,并认为FK506不是溶血性尿毒综合征(HUS)的危险因素。然而,本文报道1例在FK506治疗期间发生HUS的病人。患者,女,27岁,患急性髓细胞样白血病,1989年10月接受骨髓移值(BMT)。为预防移植物对宿主反应疾病(GVHD),每日给予3mg/kg的环孢菌素。BMT后3个月,患者出现累及皮肤的慢性GVHD、干燥眼、颊
Both McCauley et al. (1989) and Brown and Ne-ild (1990) suggest that immunosuppressive doses of FK506 do not cause vascular endothelium effects as seen in cyclosporins and consider FK506 not hemolytic uremic syndrome HUS) risk factors. However, we report 1 patient who developed HUS during FK506 treatment. Patient, female, 27 years old with acute myeloid leukemia, received bone marrow transplant (BMT) in October 1989. To prevent graft-versus-host disease (GVHD), 3 mg / kg of cyclosporine is administered daily. Three months after BMT, the patient developed chronic GVHD involving the skin, dry eyes, and cheeks